WNT1 and osteoporosis: Despite these recognized limitations, given the lack of prior data on lipocalin-2 in monogenic skeletal disorders or in relation to other bone biomarkers, and the rarity of affected mutation-positive subjects with monogenic skeletal disorders, such as WNT1 and PL3 osteoporosis, we consider our results valuable and unique.